icon
icon
icon
icon
🏷️$300 Off
🏷️$300 Off

News /

Articles /

AstraZeneca's (AZN.US) potential blockbuster ADC therapy submits an NDA to FDA

Market IntelWednesday, Nov 13, 2024 1:50 am ET
1min read

On November 13, AstraZeneca (AZN.US) and Daiichi Sankyo announced that they had submitted a biologics license application (BLA) to the U.S. FDA for datopotamab deruxtecan (Dato-DXd), a Trop2-targeting antibody-drug conjugate (ADC) jointly developed by the two companies, seeking accelerated approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations who have received systemic therapy, including EGFR-targeted therapy. At the same time, the two companies voluntarily withdrew the BLA previously submitted to the FDA for the treatment of advanced or metastatic non-squamous NSCLC.

It is known that the new BLA was mainly based on the positive results of the TROPION-Lung05 clinical 2nd phase trial and supported by the data of the TROPION-Lung01 clinical 3rd phase and TROPION-PanTumor01 clinical 1st phase trials. The TROPION-Lung05 and TROPION-Lung01 trials evaluated the efficacy and safety of datopotamab deruxtecan in EGFR-mutated NSCLC patients who had received prior systemic therapy. The combined analysis results of the two trials will be presented at the 2024 European Society for Medical Oncology (ESMO) Asia conference.

Comments

Add a public comment...
Post
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App